RE:Parsons not on ONCY board for licensing & biobuck dealsPfizer and BMS have both sought to employ what they have referred to as a“String of Pearls” strategy which is an effort to accelerate discovery and development of new therapies by partnering with or acquiring small to medium size companies. Now that Big Pharma faces a looming patent cliff, and with over 1.7 Trillion dollars of Big Pharma money in the game looking for new innovative drugs to bolster their increasingly threatened product portfolios, this 'string of pearls' strategy is being significantly accelerated. The consequence is that Big Pharma companies in general have increasingly begun to reach upstream in the discovery and development deal-making pathway with start-up and early stage companies being acquired by Big Pharma for $Billions as we have begun seeing recently, and as is expected to continue going forward.